MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
GILD   75.32 (+0.56%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
GILD   75.32 (+0.56%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
GILD   75.32 (+0.56%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
GILD   75.32 (+0.56%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

OTCMKTS:AITBAIT Therapeutics Stock Price, Forecast & News

$7.51
-0.56 (-6.94 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.00
Now: $7.51
$8.04
50-Day Range
$3.94
MA: $7.51
$9.45
52-Week Range
$3.11
Now: $7.51
$6.25
Volume314,214 shs
Average Volume19,435 shs
Market Capitalization$79.46 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.31
AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Garden City, New York.
Read More
AIT Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.59 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AITB
CUSIPN/A
CIKN/A
Phone972-8684-3313

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-18,040,000.00

Miscellaneous

Employees10
Market Cap$79.46 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AITB News and Ratings via Email

Sign-up to receive the latest news and ratings for AITB and its competitors with MarketBeat's FREE daily newsletter.

AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions

How has AIT Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

AIT Therapeutics' stock was trading at $6.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AITB shares have increased by 17.2% and is now trading at $7.51. View which stocks have been most impacted by Coronavirus.

Has AIT Therapeutics been receiving favorable news coverage?

News coverage about AITB stock has been trending somewhat negative on Thursday, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AIT Therapeutics earned a daily sentiment score of -1.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAIT Therapeutics.

Who are some of AIT Therapeutics' key competitors?

What other stocks do shareholders of AIT Therapeutics own?

Who are AIT Therapeutics' key executives?

AIT Therapeutics' management team includes the following people:
  • Mr. Steven Adam Lisi, CEO & Chairman (Age 48)
  • Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 45)
  • Mr. Douglas J. Beck, Chief Financial Officer (Age 58)
  • Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory Board
  • Dr. Giora Davidai M.D., Chief Medical Officer

What is AIT Therapeutics' stock symbol?

AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB."

How do I buy shares of AIT Therapeutics?

Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AIT Therapeutics' stock price today?

One share of AITB stock can currently be purchased for approximately $7.51.

How big of a company is AIT Therapeutics?

AIT Therapeutics has a market capitalization of $79.46 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 10 workers across the globe.

What is AIT Therapeutics' official website?

The official website for AIT Therapeutics is www.ait-therapeutics.com.

How can I contact AIT Therapeutics?

AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.